Ovarian cancer is the gynecological cancer exhibiting the highest morbidity and improvement of treatments is still required. Previous studies have shown that Estrogen-receptor beta (ERb) levels decreased along with ovarian carcinogenesis. Here, we present evidence that reintroduction of ERb in BG-1 epithelial ovarian cancer cells, which express ERa, leads in vitro to a decrease of basal and estradiol-promoted cell proliferation. ERb reduced the frequency of cells in S phase and increased the one of cells in G2/M phase. At the molecular level, we found that ERb downregulated total retinoblastoma (Rb), phosphorylated Rb and phospho-AKT cellular content as well as cyclins D1 and A2. In addition, ERb had a direct effect on ERa, by strongly inhibiting its expression and activity, which could explain part of the anti-proliferative action of ERb. By developing a novel preclinical model of ovarian cancer based on a luminescent orthotopic xenograft in athymic Nude mice, we further revealed that ERb expression reduces tumor growth and the presence of tumor cells in sites of metastasis, hence resulting in improved survival of mice. Altogether, these findings unveil a potential tumor-suppressor role of ERb in ovarian carcinogenesis, which could be of potential clinical relevance for the selection of the most appropriate treatment for patients.
Introduction
The single epithelial cell layer that surrounds ovaries is currently believed to be one of the sources of preneoplastic lesions leading rise to epithelial ovarian tumors, which represent the vast majority of ovarian cancers [1] . Epithelial ovarian cancer (EOC) is the seventh most common cancer. However, it remains the fourth most deadly one because it is difficult to diagnose at early stages and, hence, to treat [2] . Either classified on morphological categories (i.e., serous, mucinous, endometrioid, and clear cells) based on histological criteria and resemblance to epithelial components of the normal reproductive tract, or more recently, classified as low-or high-grade tumors [2] , EOC is a complex disease for which the etiology is poorly understood. Novel markers and targets for therapies are thus urgently needed.
Ovary is the main organ of production of estrogens, which mainly impact on the growth, differentiation and function of reproductive tissues [3] . Through their mitogenic action, estrogens play roles in ovarian carcinogenesis. Several studies have highlighted an increased risk of ovarian cancer in patients receiving long-term estrogen replacement therapy [4, 5, 6, 7] , while patients treated with oral contraception combining estrogens and progestins showed a reduced risk of developing an ovarian cancer [8, 9] . Estrogen action is mediated by two receptors, ERa and ERb, two transcription factors of a large family of nuclear receptors [10, 11] . About 40 to 60% of ovarian cancers express ERa [12] , but it is intriguing to notice that only a small proportion of them will benefit from anti-estrogen therapy [13] . The role of ERb in the ovarian biology remains poorly understood, but it seems to be different from that of ERa [14] . ERb knock-out animals (bERKO) are subfertile, producing fewer litters and pups upon superovulation induction [15, 16] . The ovaries of bERKO animals contain fewer large antral follicles and corpus luteum compared to wild-type littermates, which is concomitant with lower levels of estradiol produced [17] and a reduced expression of key genes involved in ovary function such as aromatase (Cyp19a1), LH receptor (Lhcgr), and prostaglandin synthase 2 (Ptgs2) [18] .
Several studies have unraveled a potential role for ERb in EOC. In particular, ERb levels were lower in ovarian tumors compared to normal tissues [19, 20, 21, 22] . Moreover, the loss of ERb expression could correlate with a shorter overall survival of ovarian cancer patients [23] . ERb levels are also associated with metastatic lymph node status [24] . A polymorphism (rs127572) of the ERb gene has also been identified recently and shown to be associated with an increased risk of developing an ovarian cancer [25] . However, it is still unknown whether this polymorphism affects the expression of ERb. The intracellular location of ERb in tumor cells seems to be important. Indeed, a recent study has shown that ERb was localized in the cytoplasm of tumor cells, while it was mainly nuclear in normal epithelial cells [26] . In addition, cytoplasmic expression of ERb was correlated to a poor outcome for patients with advanced serous ovarian cancer [14] . These findings, combined with the aforementioned clinical correlations between ERb and patient survival, lead us to hypothesize that ERb is a critical factor in ovarian tumor progression and to delineate the precise contribution of this receptor in the molecular pathways underlying EOC carcinogenesis.
For this purpose, we used BG-1 cells as a cellular model and took advantage of an orthotopic xenograft mouse model we have developed. BG-1 cell line is a human EOC cell line derived from a solid primary tumor tissue from a patient with stage III, poorly differentiated ovarian adenocarcinoma [27] . These cells express ERa and are sensitive to estrogens in terms of proliferation [21, 28] . Experimental models of ovarian carcinogenesis are essential to understand the molecular mechanisms involved in the development of the disease but also to evaluate the efficacy of novel therapeutic drugs [29] . Several models have been developed, including different xenograft and transgenic models, none being fully satisfactory. The xenograft models that are currently used are either intraperitoneal, subcutaneously or orthotopically intrabursal in the ovary. Only few reports describe orthotopic xenograft. Nevertheless, orthotopic cell implantation can be perceived as more physiological, as the cancer cells are directly inoculated in the ovarian environment and can lead to metastasis. Therefore, to investigate the role of ERb in EOC carcinogenesis, we chose to take advantage of an orthotopic xenograft mouse model based on the use of luciferase (Luc)-expressing human epithelial ovarian cancer BG-1 cells.
We show here that reintroduction of ERb in BG-1 cells using an adenovirus leads in vitro to an inhibition of both basal and estradiol-induced cell proliferation. ERb exerts its anti-proliferative action through a reduction of the frequency of cells in S phase, an increase of cells in G2 phase, along with an altered expression of cell cycle regulators. At the molecular level, ERb was able to repress the expression, the activity and the signaling of ERa, and thus to block its proliferative action. Moreover, ERb was able to strongly reduce the development of orthotopic ovarian xenograft as well as the presence of tumor cells the sites of metastasis, leading to an increased survival of the mice. Altogether, these findings support a role for ERb as tumor-suppressor in EOC carcinogenesis.
Results
Previous reports have shown that ERb is weakly expressed in EOC tissues and derived cell lines compared to normal tissue [11] . We took advantage of the human EOC cell line BG-1, which expresses endogenous levels of ERa and is sensitive to estrogens [27] . Here, we first confirm that BG-1 cells display low steady-state levels of ERb products, i.e. mRNA and proteins (Fig. 1A, B) . The next step towards assessing the role of ERb in ovarian carcinogenesis was to restore its expression in ovarian cancer cells. Thus, BG-1 cells were infected with a backbone (Ad5) or human ERb (Adb) encoding adenovirus [30, 31] . ERb overexpression was indeed obtained in Adb-infected cells as validated by real-time PCR and Western blot analyses (Fig. 1A, B) . Interestingly, ERb levels were strongly down-regulated by estradiol (E2) both at RNA and protein levels. Moreover, in the absence of ERb, ERa levels were also down-regulated by E2, although at a lesser extent. When ERb was introduced in the cells, the basal expression level of ERa in the absence of E2 was reduced and by half. The presence of ERb strongly diminished ERa levels in the presence of E2 (more than 15 fold decrease in 3 h), suggesting that ERb enhances the degradation of ERa. This is likely due to proteasome-dependent degradation of ERa and ERb proteins [32] . The effects of ERb overexpression on estrogen responsiveness were then investigated. We analyzed the ability of ERb to transactivate a synthetic luciferase reporter sensitive to estrogens in BG-1 cells. Endogenous ERa was able to activate the reporter in the presence of E2 (Fig. 1C) . ERb strongly repressed the activity of ERa in response to E2, suggesting that in the presence of ERa, ERb behaves rather as a repressor than an activator of estrogen signaling. To ensure of the functionality of the receptor produced, we also checked the activity of ERb in the EOC cell line PEO14 [33] that is reported to express low levels of ERa ( Fig. 1E ) and hence does not respond to estrogens [34] . Both ERa and ERb were able to stimulate an estrogen-sensitive reporter upon E2 exposure, even though ERb was a little bit less active than ERa (Fig. 1D) . Therefore, in the absence of ERa, ERb retains the ability to transactivate estrogen signaling pathways. When ERa and ERb were coexpressed in PEO-14 cells, the activity of the reporter in the presence of E2 was similar to the one of ERa alone. This suggests that in the ER-negative PEO-14 cell line, ERb cannot affect ERa activity. Western blot experiments in PEO-14 cells show that when ERa and ERb were expressed separately, their levels were strongly decreased in the presence of E2 (Fig. 1E) . When ERa and ERb were coexpressed, the degradation of ERa in the presence of E2 was slightly increased but not in the proportion seen in BG-1 cells. For ERb, the coexpression of ERa enhanced slightly the degradation of ERb. Overall, these data suggest that ERa levels are not regulated in the same manner in BG-1 and PEO-14 cells, which could explain why ERa activity is not drastically reduced by the presence of ERb in PEO-14 in comparison to BG-1 cells.
We next studied the effects of ERb expression on cancer cell proliferation. BG-1 cells infected with Ad5 or Adb adenoviruses were grown in vitro in the absence or the presence of E2. As expected, E2 stimulated the proliferation of control BG-1 cells ( Fig. 2A) . Interestingly, ERb repressed by 50% both the basal and E2-dependent proliferation of BG-1 cells. We also observed antiproliferative action of ERb in ERa-and ERb-negative PEO14 cells. However, this inhibition was not affected by E2 ( Figure S2 ). While the in vitro effects of ERb have been observed so far, very little is known of its in vivo action in ovarian cancer models. As a first approach to assess this point, we used a model of subcutaneous injection. To enable a sensitive, dynamic and early follow-up of tumor growth, we stably transfected BG-1 cells with a constitutive Luc reporter. Ovariectomized athymic Nude mice were implanted a pellet of cholesterol or E2 and injected with BG-1 cells infected with Ad5 or Adb adenoviruses. BG-1 cells formed tumors only in the presence of E2 (Fig. 2B ). ERb expression significantly reduced by 70% the E2-promoted growth of BG-1 cells, thus supporting a potential anti-proliferative role for ERb in EOC. We then explored the mechanisms responsible for the antitumoral action of ERb. Cell cycle distribution was compared by flow cytometry in control and ERb-expressing BG-1 cells (Fig. 3A) . We did not detect any SubG0 peak, suggesting that no apoptosis occurred. ERb expression did not modify the proportion of BG-1 cells in G0-G1 phase, but it strongly reduced that of cells in S phase. We also found that ERb expression triggered an increased number of cells in G2-M phase of cell cycle. The expression of cell cycle markers was next monitored by Western blot analyses (Fig. 3B) . Several cell cycle regulators such as Cyclins A and D1, AKT and Rb are reported to be regulated by estrogens [35] . We observed that phosphorylation of AKT was increased upon E2 treatment in Ad5-infected BG-1 cells (Fig. 3B) . ERb expression led to a decrease in phospho-AKT content in both vehicle-and E2-teated cells and this occurred at 3, 6 and 24h. ERb caused similar changes in Cyclin D1, total Rb and phosphorylated Rb expression. Indeed, the levels of cyclin D1, total Rb and phosphorylated Rb were up-regulated upon E2 treatment in Ad5 infected cells and this induction was reduced by ERb. Cyclin A2 displayed a late induction 24h after E2 treatment and this was reduced by the presence of ERb.
To further explore the in vivo role of ERb in ovarian carcinogenesis, we set up a more physiologic model of orthotopic implantation of tumor cells in the ovary. Ad5-or Adb-infected BG-1-Luc cells were injected in the left ovary and tumor growth was monitored by bioluminescence. As shown in Fig. 4A , ERb expression significantly prevented tumor growth. When euthanized at day 28 post-injection, control mice displayed a clear increase of peritoneal volume and of tumor volume in the left ovary (Fig. 4B) . In sharp contrast, the volume of both peritoneum and ovary appeared much reduced in mice injected with ERbexpressing BG-1 cells. We next determined whether the metastatic process was affected by ERb expression. To achieve this, the lung, liver and contralateral right ovary were collected. The extent of tumor cells present in these organs was estimated by measuring the Luc activity in our orthotopic model. Luciferase activity was detected in the lung, liver and contralateral ovary from mice injected with Ad5-infected BG-1 cells, (Fig. 5A) . Interestingly, ERb expression strongly reduced the presence of tumor cells and potentially metastasis to all these organs, suggesting that ERb exerts a dual role on the tumor growth and dissemination. This was confirmed by in vitro wound healing experiments showing that ERb expression decreases the motility of BG-1 cells (data not shown). Since ERb impacted on both tumor growth and cell dissemination, we wondered whether this could enable to improve mice survival. Mice were followed-up for 80 days and daily checked for any sign of morbidity. ERb expression significantly delayed death as two months after injection with Adb-infected BG-1 cells, 50% of mice still survived (Fig. 5B) . This is in strong contrast with the 100% death of control mice, which occurs in less than two months.
Discussion
We report here that the introduction of ERb in ovarian cancer cells displaying endogenous levels of ERa leads to a strong inhibition of in vivo growth and cell dissemination, mediated through the control of ERa expression and signaling.
In vitro proliferation experiments show a clear inhibition of the E2-dependent proliferation by ERb in the ERa-positive ovarian cancer cell line BG-1. This is the first demonstration of an antiproliferative action of ERb in an ERa-positive ovarian cancer cell line. Moreover, ERb could also inhibit the growth of the ERanegative ovarian cancer cell line PEO-14. These results are in agreement with our previous findings obtained with ERa-negative cell lines from breast [31] and prostate [30] cancer cells and with another study performed in ERa-negative SKOV3 EOC-derived cell line [36] . In cells devoid of estrogen receptors, it is likely that restoration of ERa cannot enable a stimulation of proliferation upon E2 treatment, since it triggers a different program of transcriptional regulation, compared to cells expressing naturally ERa, as previously showed in breast cancer cells [37] . Indeed, we observed that endogenous ERa levels in BG-1 cells were strongly reduced by the presence of ERb, whereas ERb affected less ERa levels in PEO-14 cells. Moreover, ERb could inhibit completely ERa activity in BG-1 cells but not in PEO-14 cells. This could be due to the fact that in BG-1 cells, endogenous ERa is under the control of its own promoter, whereas in PEO-14 cells, exogenous ERa is controlled by a viral promoter. Moreover, one cannot exclude that the cofactors required for ERa and ERb activity in the two cell types are different, which accounts for their differential activity in the BG-1 and PEO-14 cells.
The novelty of our study is to have extended these data to two in vivo models. If clinical evidences based on ERb levels in normal tissue and cancer suggest that this receptor could act as a potential tumor suppressor, so far, no preclinical proof has been brought to confirm this hypothesis. We first used a classical subcutaneous model, to answer to this question and more precisely to determine if estrogen were required or not. BG-1 in vivo growth was clearly dependent on the presence of estradiol and ERb could counteract tumor growth. We also used orthotopic implantation of bioluminescent cells in the ovary. In agreement with in vitro experiments, we observed a strong reduction of tumor growth when BG-1 cells express ERb.
Cell cycle analysis demonstrated that ERb inhibited cell proliferation, by decreasing the proportion of cells in S phase and increasing the proportion of cells in G2-M phase. This situation is similar to that reported in breast cancer cells [38] . At the molecular level, ERb could decrease the phosphorylation of Akt and Rb. In addition, ERb also reduced the expression of cyclin D1 and cyclin A. Cyclin D1 interacts with CyclinDependent Kinase-4 and 26, which leads to the phosphorylation of Rb and the dissociation of Rb/E2F complex, which causes the progression through the G1 [35] . Cyclin A interacts with CyclinDependent Kinase-2 to promote the transition from the S to G2 phase [39] . Moreover, the phosphorylation of AKT favors G1/S transition by blocking the transcriptional activity of Foxo factors, which regulate Cyclin D1 and p21 expression [40] . Based on these findings, we propose that ERb leads to a decrease in AKT phosphorylation, which in turn results in a decreased expression of Cyclin D1 and phosphorylation of Rb.
To explain how ERb can affect cell proliferation, we have investigated whether it could directly modify ERa expression and signaling in BG-1 cells. It is indeed interesting to notice that ERb has also profound effects of ERa levels as it diminished by about 15 fold ERa expression in 3h. Although the exact molecular mechanisms accounting for the negative effect of ERb on ERa in BG-1 cells remains to be elucidated, the extent and rate of degradation of ERa is certainly critical for its activity and these parameters change if ERb is present or not. Indeed, in parental BG-1 cells, expressing only ERa, the receptor is also subjected to E2-dependent degradation. This is likely due to proteasomal degradation of the receptor as shown in a number of cell types by previous studies [41, 42] . Paradoxically, the E2-dependent proteasomal degradation of ERa is also required for its full activity through the regulation of the interactions of the receptors with its coactivators [42] and the cycling of ERa on the promoter of its target genes [43] . The situation appears different when ERb is coexpressed with ERa in BG-1 cells. Indeed, we report that ERb could reduce more rapidly and strongly the expression of ERa in BG-1 cells in the presence of E2, compared to cells in which only ERa is present. This is in agreement with what is observed in the ERa-positive breast cancer cell line T47-D transfected with ERb [44] . This suggests that ERb could trigger a rapid proteasomal degradation of ERa in the presence of E2. If we suppose that ERa and ERb form heterodimers as previously described [45, 46] , ERb might increase the degradation of ERa present in the complex, by altering its conformation and preventing it from being active. Consequently, ERa would be less efficient to activate its target genes and could not play its proliferative role.
Indeed, in addition to its effects on ERa expression, we cannot exclude that ERb also reduces ERa activity, as shown by transfection of an estrogen-responsive reporter in BG-1 cells. This is in agreement with a previous study performed in an ERapositive breast cancer cell lines in which ERb was transfected, suggesting that ERa and ERb have distinct roles [47] . In turn, this could affect the E2-dependent signaling of ERa, which could not regulate the levels of the activity of key target genes involved in the proliferation, such as AKT, Rb, cyclin D1 or cyclin A2. Moreover, other studies have reported a negative action of ERb on ERa signaling [44, 48] . In particular, ERb has been shown to alter the recruitment of AP-1 complexes to ERa target genes [44] , which is known to act in synergy with ERa. Once heterodimerized with ERa, ERb could also modify the ability of ERa to interact with coactivators. A previous study has also suggested a Ying Yang action of ERb in vivo, which is a repressor of ERa signaling in the presence of ERa, but can also replace ERa in the absence of ERa [48] . The down-regulation of ERa expression by ERb may not be the only mechanism of growth inhibition by ERb, as ERb can also reduce cell growth of ERa-negative PEO-14 cells. It is possible that ERb directly affect factors involved in cell proliferation, such as transcriptional coregulators, cell cycle regulators but also growth factors.
We report that ERb could not only reduce the growth of the primary tumor, but could also decrease the extent of metastasis, or at least the presence of tumor cells in different organs. We have previously shown that ERb could inhibit in vitro cancer cell invasion [31] , which certainly accounts for the decreased dissemination observed. However, we cannot completely exclude the possibility that the reduced growth of the primary tumor leads also to a decreased metastasis. Whatever the effect exerted by ERb, this reduction of metastasis certainly explains the increased survival of the mice implanted with ERb cells.
Taken together, our findings provide evidence for a scenario in which ERb acts as a potential tumor-suppressor and represents a potential target for future therapies of EOC. To our knowledge, this is the first in vivo demonstration of anti-proliferative andmetastatic actions of ERb in a preclinical orthotopic model of ovarian carcinogenesis. Our results linking ERb and the mestastasis process are in complete agreement with clinical studies revealing that ERb is not expressed in metastatic forms of ovarian cancers [20] and the loss of its expression correlates with a shorter overall survival [23] . Here, we further unravel that ERb directly impacts on ERa expression, cell cycle and invasive properties of cancer cells. The reasons accounting for the weak expression of ERb in ovarian cancer remain elusive. Recent reports suggest possible epigenetic modifications leading to ERb silencing, as treatment of ovarian cancer cells with DNA methyltransferase or histone deacetylase inhibitors could restore its expression [49, 50, 51] . Another hypothesis would be a preferential degradation of ERb protein by the proteasome, resulting in low levels of this receptor in cancer cells [32] . These could be the tracks to explore in the future for controlling ERb expression and developing novel therapies in ovarian cancer.
Materials and Methods

Tumor cell line
The human ovarian cell lines BG-1 (ERa-positive cells) [52] or PEO14 [33] were obtained from Dr. P Pujol [52] and grown in DMEM supplemented with 10% FCS and gentamycin at 37uC in a humidified atmosphere containing 5% CO 2 . To wean the cells off steroids, they were cultured in phenol red-free DMEM-F12 supplemented with 10% charcoal dextran-treated FCS (CDFCS) for 4 days.
The stably transfected BG-1-luc cell line was obtained after transfection with the plasmid CMV-LUC-Neo encoding the luciferase reporter under the control of CMV promoter. Transfected cells were then selected by G418 at a concentration of 0.5 mg/ml. Luminescent clones were identified using photoncounting camera (NightOWL II LB 983 from Berthold, France) by addition of luciferin in the growth medium, and the most responsive clones were isolated.
RNA extraction and real-time PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) as described by the manufacturer. Reverse transcription was performed using random primers and Superscript II enzyme (Invitrogen). Real-time PCR quantification was then performed using a SYBR Green approach (Light Cycler; Roche), as previously described [53] . For each sample, ERa and ERb mRNA levels were normalized with RS9 mRNA levels. The sequences of the oligonucleotides used were previously described [49] .
Recombinant adenovirus construction, propagation and infection
The non-recombinant adenovirus Ad5, and the adenovirus encoding ERa (Ada) or ERb (Adb) used in this study have been previously described [31] . BG-1 cells were infected overnight at a multiplicity of infection (MOI) of 25 and PEO-14 at a MOI of 100 in DMEM/F12 10% CDFCS.
Constructs and Transient transfection
The ERE-TK-LUC construct consists of two ERE in tandem upstream of TK promoters [49] . 3.10 5 of steroid-weaned cells were plated in 12-well plates in phenol red-free DMEM-F12, and supplemented with 10% CDFCS 24 h before transfection. Cells were infected with Ad5, Ada or Adb viruses as mentioned above. Transfections were performed using lipofectamine according to the manufacturer's recommendations, using 2 mg of the luciferase reporter, along with 0.5 mg of the internal reference reporter plasmid (CMV-Gal) per well. After 6 h incubation, the medium was removed and the cells were placed into a fresh medium supplemented with a control vehicle (ethanol) or E2. Twenty-four hours later, cells were harvested and assayed for luciferase activity using a Centro LB960 Berthold luminometer. b-galactosidase was determined as previously described [49] .
Protein extracts and Western blots
BG-1 cells were cultured for 4 days in CDFCS. Cells were treated for 24h with 4 mM thymidine before adenoviral infection with Ad5 or Adb viruses. Cells were harvested in Tris-glycerol buffer (Tris-HCl 50mM, EDTA 1.5mM, 10% glycerol) supplemented with protease inhibitor cocktail (Roche) and phosphatase inhibitors, and were then sonicated. 30 mg of protein extracts were subjected to SDS-PAGE protein samples Western blot analyses were done using ERa 
Flow cytometry 1x10
6 BG-1 were collected 24h after infection with Ad5 or Adb adenoviruses. Cells were resuspended in 75% ethanol and fixed for 12 min. After centrifugation, cells were incubated in PBS containing 40 mg/ml propidium iodide and 100 mg/ml RNAse for half an hour at 37uC. Cell cycle analysis was performed on an Epics-XL flow cytometer (Beckman Coulter, Fullerton, CA, USA) and analyzed with Modfit software (Verity Software, Topsham, ME, USA).
Animal xenografts
Female Nu/Foxn1 athymic nude mice, 7 weeks old were obtained from Harlan. Mice were acclimatized for 1 week before the experiment, and were kept under pathogen-free conditions in laminar-flow boxes (5 mice/cage) maintained under standard conditions (2262 uC, 45610% relative humidity, 12 h light/12 h dark cycle each day, standard diet and water ad libitum). All experiments were performed in accordance with the French guidelines for experimental animal studies and declared to ethical committee (Comité d'Ethique pour l'Expérimentation Animale Languedoc Roussillon (CEEA-LR)) (Permit No. obtained for this study: CEEA-LR-11014). All efforts were made to minimize suffering.
When indicated, before cell implantation, a silicone tube (silastic) filled with a solid mixture of E2 and cholesterol as a carrier (1:10) was implanted subcutaneously (sc) in the interscapular region of ovariectomized mice as previously described [54] . Two days later, 5.10 6 BG-1 cells prepared in 75 ml serum-free culture medium, combined with phenol red free Matrigel (1:1, v/v, BD Biosciences) were sc grafted on both flanks of these mice. Alternatively, 1.10 6 BG-1 cells prepared in 20 ml serum-free culture medium combined with matrigel (2:1, v/v) were orthotopically grafted in the left ovary surgically exposed of anaesthetized mice.
In vivo bioluminescent imaging BG-1 cells
To measure luciferase activity, mice were first sedated by isoflurane gas anesthesia system (T.E.M., Bordeaux, France). Mice were then injected intraperitoneally with 125 mg/kg body weight of luciferin (sodium salt; Promega) in aqueous solution. Luminescence was measured using NightOWL II LB 981 CCD camera and integrated for a 5-min period. The signal intensities from regions of interest (ROI) were obtained and data were expressed as photon (Ph/s). Background was defined from a region of the same size placed in a non-luminescent area nearby the animal and then subtracted from the measured luminescent signal intensity. The correlation of luciferase signal with tumor volume and weight was demonstrated ( Figure S1 ).
Tissues extracts luciferase activity
Lysates from tissue samples were prepared in ceramic beadscontaining tubes (Lysing matrix, MP Biomedicals), by disruption in luciferase lysis buffer (25mM Tris Phosphate pH7.8, 2 mM DTT, 2 mM EDTA, 10% Glycerol, 1% Triton X100, 1mg/ml BSA). The samples were subjected to two oscillations at 7,000 r/ min for 15 seconds. The lysates were then centrifuged at 10,000 rpm for 30 min at 4uC, and the supernatant was saved and assayed. 10 ml of the supernatant were loaded onto 96-well white opaque tissue plates (Lumitrac 200), and luciferase activity was measured as previously described [49] . 
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